1	Promoting	Promote	B-VP	VBG	O	0	ROOT	17	Promoting
2	angiogenesis	angiogenesis	B-NP	NN	O	1	OBJ	3	angiogenesis
3	via	via	B-PP	IN	O	1	VMOD	0
4	manipulation	manipulation	B-NP	NN	O	3	PMOD	16	manipulation
5	of	of	B-PP	IN	O	4	NMOD	-1
6	VEGF	VEGF	B-NP	NN	B-protein	7	NMOD	-1
7	responsiveness	responsiveness	I-NP	NN	O	5	PMOD	0
8	with	with	B-PP	IN	O	4	NMOD	-1
9	notch	notch	B-NP	NN	O	10	NMOD	-1
10	signaling	signaling	I-NP	NN	O	8	PMOD	0
11	.	.	O	.	O	1	P	-1

1	Promoting	Promote	B-VP	VBG	O	17	SUB	17	Promoting
2	angiogenesis	angiogenesis	B-NP	NN	O	1	OBJ	3	angiogenesis
3	via	via	B-PP	IN	O	1	VMOD	0
4	delivery	delivery	B-NP	NN	O	3	PMOD	14	delivery
5	of	of	B-PP	IN	O	4	NMOD	-1
6	vascular	vascular	B-NP	JJ	B-protein	9	NMOD	-1
7	endothelial	endothelial	I-NP	JJ	I-protein	9	NMOD	-1
8	growth	growth	I-NP	NN	I-protein	9	NMOD	0
9	factor	factor	I-NP	NN	I-protein	5	PMOD	-1
10	(	(	O	(	O	12	DEP	-1
11	VEGF	VEGF	B-NP	NN	B-protein	12	DEP	-1
12	)	)	O	)	O	9	NMOD	-1
13	and	and	O	CC	O	16	NMOD	-1
14	other	other	B-NP	JJ	O	16	NMOD	-1
15	angiogenic	angiogenic	I-NP	JJ	B-protein	16	NMOD	3	angiogenic
16	factors	factor	I-NP	NNS	I-protein	9	NMOD	-1
17	is	be	B-VP	VBZ	O	0	ROOT	-1
18	both	both	O	CC	O	17	PRD	-1
19	a	a	B-NP	DT	O	21	NMOD	-1
20	potential	potential	I-NP	JJ	O	21	NMOD	0
21	therapy	therapy	I-NP	NN	O	28	NMOD	0
22	for	for	B-PP	IN	O	21	NMOD	-1
23	cardiovascular	cardiovascular	B-NP	JJ	O	24	NMOD	-1
24	diseases	disease	I-NP	NNS	O	22	PMOD	-1
25	and	and	O	CC	O	28	NMOD	-1
26	a	a	B-NP	DT	O	28	NMOD	-1
27	critical	critical	I-NP	JJ	O	28	NMOD	0
28	aspect	aspect	I-NP	NN	O	18	PRD	-1
29	for	for	B-PP	IN	O	28	NMOD	-1
30	tissue	tissue	B-NP	NN	O	31	NMOD	-1
31	regeneration	regeneration	I-NP	NN	O	29	PMOD	2	regeneration
32	.	.	O	.	O	17	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	recent	recent	I-NP	JJ	O	3	NMOD	-1
3	demonstration	demonstration	I-NP	NN	O	17	SUB	-1
4	that	that	B-SBAR	IN	O	3	NMOD	-1
5	VEGF	VEGF	B-NP	NN	B-protein	6	NMOD	-1
6	signaling	signaling	I-NP	NN	O	7	SUB	0
7	is	be	B-VP	VBZ	O	4	SBAR	-1
8	modulated	modulate	I-VP	VBN	O	7	VC	16	modulated
9	by	by	B-PP	IN	O	8	VMOD	-1
10	the	the	B-NP	DT	O	13	NMOD	-1
11	Notch	Notch	I-NP	NN	O	13	NMOD	-1
12	signaling	signaling	I-NP	NN	O	13	NMOD	0
13	pathway	pathway	I-NP	NN	O	9	PMOD	0
14	,	,	O	,	O	3	P	-1
15	however	however	B-ADVP	RB	O	17	VMOD	-1
16	,	,	O	,	O	17	P	-1
17	suggests	suggest	B-VP	VBZ	O	0	ROOT	-1
18	that	that	B-SBAR	IN	O	17	VMOD	-1
19	inhibiting	inhibit	B-VP	VBG	O	22	SUB	18	inhibiting
20	Notch	Notch	B-NP	NN	O	21	NMOD	-1
21	signaling	signaling	I-NP	NN	O	19	OBJ	0
22	may	may	B-VP	MD	O	18	SBAR	-1
23	enhance	enhance	I-VP	VB	O	22	VC	17	enhance
24	regional	regional	B-NP	JJ	O	25	NMOD	-1
25	neovascularization	neovascularization	I-NP	NN	O	23	OBJ	3	neovascularization
26	,	,	O	,	O	23	P	-1
27	by	by	B-PP	IN	O	23	VMOD	-1
28	altering	alter	B-VP	VBG	O	27	PMOD	-1
29	the	the	B-NP	DT	O	30	NMOD	-1
30	responsiveness	responsiveness	I-NP	NN	O	28	OBJ	16	responsiveness
31	of	of	B-PP	IN	O	30	NMOD	-1
32	local	local	B-NP	JJ	B-cell_type	34	NMOD	-1
33	endothelial	endothelial	I-NP	JJ	I-cell_type	34	NMOD	-1
34	cells	cell	I-NP	NNS	I-cell_type	31	PMOD	-1
35	to	to	B-PP	TO	O	30	NMOD	-1
36	angiogenic	angiogenic	B-NP	JJ	O	37	NMOD	3	angiogenic
37	stimuli	stimulus	I-NP	NNS	O	35	PMOD	-1
38	.	.	O	.	O	17	P	-1

1	We	We	B-NP	PRP	O	2	SUB	-1
2	tested	test	B-VP	VBD	O	0	ROOT	-1
3	this	this	B-NP	DT	O	4	NMOD	-1
4	possibility	possibility	I-NP	NN	O	2	OBJ	-1
5	with	with	B-PP	IN	O	4	NMOD	-1
6	in	in	B-NP	FW	O	7	AMOD	-1
7	vitro	vitro	I-NP	FW	O	8	NMOD	-1
8	assays	assay	I-NP	NNS	O	5	PMOD	-1
9	using	use	B-VP	VBG	O	8	NMOD	-1
10	human	human	B-NP	JJ	B-cell_type	12	NMOD	-1
11	endothelial	endothelial	I-NP	JJ	I-cell_type	12	NMOD	-1
12	cells	cell	I-NP	NNS	I-cell_type	9	OBJ	-1
13	,	,	O	,	O	14	P	-1
14	as	as	B-CONJP	RB	O	4	NMOD	-1
15	well	well	I-CONJP	RB	O	14	DEP	-1
16	as	as	I-CONJP	IN	O	14	DEP	-1
17	in	in	B-PP	IN	O	14	DEP	-1
18	a	a	B-NP	DT	O	22	NMOD	-1
19	rodent	rodent	I-NP	NN	O	22	NMOD	-1
20	hindlimb	hindlimb	I-NP	NN	O	22	NMOD	-1
21	ischemia	ischemia	I-NP	NN	O	22	NMOD	-1
22	model	model	I-NP	NN	O	17	PMOD	-1
23	.	.	O	.	O	14	P	-1

1	Treatment	Treatment	B-NP	NN	O	15	SUB	19	Treatment
2	of	of	B-PP	IN	O	1	NMOD	-1
3	cultured	culture	B-NP	VBN	B-cell_line	6	NMOD	19	cultured
4	human	human	I-NP	JJ	I-cell_line	6	NMOD	-1
5	endothelial	endothelial	I-NP	JJ	I-cell_line	6	NMOD	-1
6	cells	cell	I-NP	NNS	I-cell_line	2	PMOD	-1
7	with	with	B-PP	IN	O	1	NMOD	-1
8	DAPT	DAPT	B-NP	NN	O	13	NMOD	-1
9	,	,	O	,	O	13	P	-1
10	a	a	B-NP	DT	O	13	NMOD	-1
11	gamma	gamma	I-NP	NN	O	13	NMOD	-1
12	secretase	secretase	I-NP	NN	O	13	NMOD	-1
13	inhibitor	inhibitor	I-NP	NN	O	7	PMOD	0
14	,	,	O	,	O	13	P	-1
15	increased	increase	B-VP	VBD	O	0	ROOT	17	increased
16	cell	cell	B-NP	NN	O	17	NMOD	-1
17	migration	migration	I-NP	NN	O	20	NMOD	14	migration
18	and	and	O	CC	O	20	NMOD	-1
19	sprout	sprout	B-NP	NN	O	20	NMOD	-1
20	formation	formation	I-NP	NN	O	15	OBJ	2	formation
21	in	in	B-PP	IN	O	15	VMOD	-1
22	response	response	I-PP	NN	O	21	PMOD	0
23	to	to	I-PP	TO	O	21	PMOD	-1
24	VEGF	VEGF	B-NP	NN	B-protein	25	NMOD	-1
25	stimulation	stimulation	I-NP	NN	O	21	PMOD	17	stimulation
26	with	with	B-PP	IN	O	25	NMOD	-1
27	a	a	B-NP	DT	O	29	NMOD	-1
28	biphasic	biphasic	I-NP	JJ	O	29	NMOD	-1
29	dependence	dependence	I-NP	NN	O	26	PMOD	-1
30	on	on	B-PP	IN	O	29	NMOD	-1
31	DAPT	DAPT	B-NP	NN	O	32	NMOD	-1
32	concentration	concentration	I-NP	NN	O	30	PMOD	-1
33	.	.	O	.	O	15	P	-1

1	Further	Further	B-ADVP	RB	O	21	VMOD	-1
2	,	,	O	,	O	21	P	-1
3	delivery	delivery	B-NP	NN	O	21	SUB	0
4	of	of	B-PP	IN	O	3	NMOD	-1
5	an	an	B-NP	DT	O	7	NMOD	-1
6	appropriate	appropriate	I-NP	JJ	O	7	NMOD	-1
7	combination	combination	I-NP	NN	O	4	PMOD	-1
8	of	of	B-PP	IN	O	7	NMOD	-1
9	DAPT	DAPT	B-NP	NN	O	11	NMOD	-1
10	and	and	I-NP	CC	O	11	NMOD	-1
11	VEGF	VEGF	I-NP	NN	B-protein	8	PMOD	-1
12	from	from	B-PP	IN	O	11	NMOD	-1
13	an	an	B-NP	DT	O	17	NMOD	-1
14	injectable	injectable	I-NP	JJ	O	17	NMOD	-1
15	alginate	alginate	I-NP	NN	O	17	NMOD	-1
16	hydrogel	hydrogel	I-NP	NN	O	17	NMOD	-1
17	system	system	I-NP	NN	O	12	PMOD	0
18	into	into	B-PP	IN	O	3	NMOD	-1
19	ischemic	ischemic	B-NP	JJ	O	20	NMOD	-1
20	hindlimbs	hindlimb	I-NP	NNS	O	18	PMOD	-1
21	led	lead	B-VP	VBD	O	0	ROOT	0
22	to	to	B-PP	TO	O	21	VMOD	-1
23	a	a	B-NP	DT	O	25	NMOD	-1
24	faster	fast	I-NP	JJR	O	25	NMOD	-1
25	recovery	recovery	I-NP	NN	O	22	PMOD	-1
26	of	of	B-PP	IN	O	25	NMOD	-1
27	blood	blood	B-NP	NN	O	28	NMOD	-1
28	flow	flow	I-NP	NN	O	26	PMOD	-1
29	than	than	B-PP	IN	O	25	NMOD	-1
30	VEGF	VEGF	B-NP	NN	B-protein	32	NMOD	-1
31	or	or	I-NP	CC	O	32	NMOD	-1
32	DAPT	DAPT	I-NP	NN	O	29	SBAR	-1
33	alone	alone	B-ADVP	RB	O	32	NMOD	-1
34	;	;	O	:	O	21	P	-1
35	perfusion	perfusion	B-NP	NN	O	36	NMOD	0
36	levels	level	I-NP	NNS	O	21	VMOD	-1
37	reached	reach	B-VP	VBD	O	36	NMOD	-1
38	80	80	B-NP	CD	O	39	NMOD	-1
39	%	%	I-NP	NN	O	37	OBJ	-1
40	of	of	B-PP	IN	O	39	NMOD	-1
41	the	the	B-NP	DT	O	43	NMOD	-1
42	normal	normal	I-NP	JJ	O	43	NMOD	-1
43	level	level	I-NP	NN	O	40	PMOD	-1
44	by	by	B-PP	IN	O	37	VMOD	-1
45	week	week	B-NP	NN	O	44	PMOD	-1
46	4	4	I-NP	CD	O	45	NMOD	-1
47	with	with	B-PP	IN	O	37	VMOD	-1
48	combined	combine	B-NP	VBN	O	52	NMOD	-1
49	DAPT	DAPT	I-NP	NN	O	52	NMOD	-1
50	and	and	I-NP	CC	O	52	NMOD	-1
51	VEGF	VEGF	I-NP	NN	O	52	NMOD	-1
52	delivery	delivery	I-NP	NN	O	47	PMOD	14	delivery
53	.	.	O	.	O	21	P	-1

1	Direct	Direct	B-NP	JJ	O	4	AMOD	-1
2	intramuscular	intramuscular	I-NP	JJ	O	4	AMOD	-1
3	or	or	I-NP	CC	O	4	AMOD	-1
4	intraperitoneal	intraperitoneal	I-NP	JJ	O	5	NMOD	-1
5	injection	injection	I-NP	NN	O	8	SUB	19	injection
6	of	of	B-PP	IN	O	5	NMOD	-1
7	DAPT	DAPT	B-NP	NN	O	6	PMOD	-1
8	did	do	B-VP	VBD	O	0	ROOT	-1
9	not	not	I-VP	RB	O	8	VMOD	-1
10	result	result	I-VP	VB	O	8	VC	-1
11	in	in	B-PP	IN	O	10	VMOD	-1
12	the	the	B-NP	DT	O	14	NMOD	-1
13	same	same	I-NP	JJ	O	14	NMOD	-1
14	level	level	I-NP	NN	O	11	PMOD	-1
15	of	of	B-PP	IN	O	14	NMOD	-1
16	improvement	improvement	B-NP	NN	O	15	PMOD	-1
17	,	,	O	,	O	10	P	-1
18	suggesting	suggest	B-VP	VBG	O	10	VMOD	-1
19	that	that	B-SBAR	IN	O	18	VMOD	-1
20	appropriate	appropriate	B-NP	JJ	O	21	NMOD	-1
21	presentation	presentation	I-NP	NN	O	28	SUB	-1
22	of	of	B-PP	IN	O	21	NMOD	-1
23	DAPT	DAPT	B-NP	NN	O	22	PMOD	-1
24	(	(	O	(	O	27	DEP	-1
25	gel	gel	B-NP	NN	O	26	NMOD	-1
26	delivery	delivery	I-NP	NN	O	27	DEP	0
27	)	)	O	)	O	23	NMOD	-1
28	is	be	B-VP	VBZ	O	19	SBAR	-1
29	important	important	B-ADJP	JJ	O	28	PRD	0
30	for	for	B-PP	IN	O	29	AMOD	-1
31	its	its	B-NP	PRP$	O	32	NMOD	-1
32	activity	activity	I-NP	NN	O	30	PMOD	0
33	.	.	O	.	O	8	P	-1

1	DAPT	DAPT	B-NP	NN	O	2	NMOD	-1
2	delivery	delivery	I-NP	NN	O	7	SUB	14	delivery
3	from	from	B-PP	IN	O	2	NMOD	-1
4	the	the	B-NP	DT	O	5	NMOD	-1
5	hydrogels	hydrogel	I-NP	NNS	O	3	PMOD	-1
6	also	also	B-ADVP	RB	O	7	VMOD	-1
7	did	do	B-VP	VBD	O	0	ROOT	-1
8	not	not	I-VP	RB	O	7	VMOD	-1
9	lead	lead	I-VP	VB	O	7	VC	0
10	to	to	B-PP	TO	O	9	VMOD	-1
11	any	any	B-NP	DT	O	14	NMOD	-1
12	adverse	adverse	I-NP	JJ	O	14	NMOD	-1
13	side	side	I-NP	NN	O	14	NMOD	-1
14	effects	effect	I-NP	NNS	O	10	PMOD	0
15	,	,	O	,	O	14	P	-1
16	in	in	B-PP	IN	O	14	NMOD	-1
17	contrast	contrast	B-NP	NN	O	16	PMOD	-1
18	to	to	B-PP	TO	O	17	NMOD	-1
19	systemic	systemic	B-NP	JJ	O	20	NMOD	-1
20	introduction	introduction	I-NP	NN	O	18	PMOD	17	introduction
21	of	of	B-PP	IN	O	20	NMOD	-1
22	DAPT	DAPT	B-NP	NN	B-protein	21	PMOD	-1
23	.	.	O	.	O	7	P	-1

1	Altogether	Altogether	B-ADVP	RB	O	5	VMOD	-1
2	,	,	O	,	O	5	P	-1
3	these	these	B-NP	DT	O	4	NMOD	-1
4	results	result	I-NP	NNS	O	5	SUB	0
5	suggest	suggest	B-VP	VBP	O	0	ROOT	-1
6	a	a	B-NP	DT	O	8	NMOD	-1
7	new	new	I-NP	JJ	O	8	NMOD	-1
8	approach	approach	I-NP	NN	O	5	OBJ	-1
9	to	to	B-VP	TO	O	10	VMOD	-1
10	promote	promote	I-VP	VB	O	8	NMOD	17	promote
11	angiogenesis	angiogenesis	B-NP	NN	O	10	OBJ	3	angiogenesis
12	by	by	B-PP	IN	O	10	VMOD	-1
13	controlling	control	B-VP	VBG	O	12	PMOD	16	controlling
14	Notch	Notch	B-NP	NN	O	15	NMOD	-1
15	signaling	signaling	I-NP	NN	O	13	OBJ	0
16	,	,	O	,	O	5	P	-1
17	and	and	O	CC	O	5	VMOD	-1
18	may	may	B-VP	MD	O	5	VMOD	-1
19	provide	provide	I-VP	VB	O	18	VC	-1
20	new	new	B-NP	JJ	O	21	NMOD	-1
21	options	option	I-NP	NNS	O	19	OBJ	-1
22	to	to	B-VP	TO	O	23	VMOD	-1
23	treat	treat	I-VP	VB	O	21	NMOD	19	treat
24	patients	patient	B-NP	NNS	O	23	OBJ	-1
25	with	with	B-PP	IN	O	24	NMOD	-1
26	diseases	disease	B-NP	NNS	O	25	PMOD	-1
27	that	that	B-NP	WDT	O	26	NMOD	-1
28	diminish	diminish	B-VP	VBP	O	27	SBAR	18	diminish
29	angiogenic	angiogenic	B-NP	JJ	O	30	NMOD	3	angiogenic
30	responsiveness	responsiveness	I-NP	NN	O	28	OBJ	0
31	.	.	O	.	O	5	P	-1

